Table 2.
Cohort Demographics for Users of Inhaled TOB or AZLI, Matched (≥1-Year Follow-up)
| Inhaled TOB |
Inhaled AZLI |
|||
|---|---|---|---|---|
| Low AZM (n = 1,951) | High AZM (n = 1,951) | Low AZM (n = 436) | High AZM (n = 436) | |
| Follow-up years, mean (SD) | 2.46 (1.53) | 2.68 (1.60) | 2.06 (1.22) | 2.29 (1.26) |
| Baseline age, mean (SD)* | 16.7 (10.26) | 16.8 (9.89) | 23.0 (13.6) | 23.2 (13.6) |
| Best 6-mo FEV1pp, mean (SD)* | 84.1 (21.4) | 84.2 (21.0) | 75.8 (24.4) | 75.0 (24.9) |
| Any lumacaftor/ivacaftor use | 258 (13.2) | 266 (13.6) | 65 (14.9) | 62 (14.2) |
| PE prior 12 mo | ||||
| 0 | 1,220 (62.5) | 1,202 (61.6) | 231 (53.0) | 221 (50.7) |
| 1–2 | 631 (32.3) | 643 (33.0) | 170 (39.0) | 184 (42.2) |
| ≥3 | 100 (5.1) | 106 (5.4) | 35 (8.0) | 31 (7.1) |
| Sex, M | 994 (50.9) | 1,016 (52.1) | 195 (44.7) | 184 (42.2) |
| Nonwhite or Hispanic | 335 (17.2) | 342 (17.5) | 49 (11.2) | 56 (12.8) |
| Mutation class | ||||
| 1–3 | 1,562 (80.1) | 1,594 (81.7) | 357 (81.9) | 350 (80.3) |
| 4–5 | 85 (4.4) | 71 (3.6) | 22 (5.0) | 31 (7.1) |
| Other | 278 (14.2) | 264 (13.5) | 57 (13.1) | 55 (12.6) |
| Baseline year in 2013–2016† | 702 (36.0) | 666 (34.1) | 202 (46.3) | 189 (43.3) |
| Dornase alfa | 1,687 (86.5) | 1,720 (88.2) | 375 (86.0) | 384 (88.1) |
| Pancreatic enzymes | 1,716 (88.0) | 1,731 (88.7) | 392 (89.9) | 401 (92.0) |
| CF liver disease | 154 (7.9) | 141 (7.2) | 45 (10.3) | 35 (8.0) |
| CF-related diabetes | 240 (12.3) | 225 (11.5) | 101 (23.2) | 93 (21.3) |
| Hypertonic saline | 1,005 (51.5) | 1,058 (54.2) | 262 (60.1) | 293 (67.2) |
| Insurance | ||||
| Private | 1,146 (58.7) | 1,174 (60.2) | 295 (67.7) | 285 (65.4) |
| Medicare | 66 (3.4) | 66 (3.4) | 21 (4.8) | 26 (6.0) |
| Medicaid | 638 (32.7) | 604 (31.0) | 89 (20.4) | 96 (22.0) |
| Other/no insurance | 101 (5.2) | 107 (5.5) | 31 (7.1) | 29 (6.7) |
| BMI percentile (aged <20 yr), mean (SD) | 49.4 (27.4) | 49.5 (26.8) | 48.8 (27.4) | 50.9 (26.1) |
| BMI (aged ≥20 yr), mean (SD) | 22.6 (3.9) | 22.8 (3.4) | 23.1 (4.0) | 22.8 (3.7) |
Definition of abbreviations: AZLI = aztreonam lysine; AZM = azithromycin; BMI = body mass index; CF = cystic fibrosis; FEV1pp = FEV1 percentage predicted; PE = pulmonary exacerbation events; TOB = tobramycin.
Data provided as n (%) unless otherwise specified.
*
Exact matching within age groups (6–35, 36–40 yr) and within groups for best FEV1pp in the past 6 mo (<60%, 60% to <80%, 80% to <90%, 90% to <100%, ≥100%).
†
Reference group: baseline year 2010–2012.